GSK269962 HCl structure
|
Common Name | GSK269962 HCl | ||
---|---|---|---|---|
CAS Number | 2095432-71-4 | Molecular Weight | 607.06 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C29H31ClN8O5 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of GSK269962 HClGSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities[1]. |
Name | GSK269962A hydrochloride |
---|
Description | GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities[1]. |
---|---|
Related Catalog | |
Target |
ROCK1:1.6 nM (IC50) ROCK2:4 nM (IC50) RSK1:132 nM (IC50) MSK1:49 nM (IC50) AKT1:955 nM (IC50) AKT2:1350 nM (IC50) AKT3:1510 nM (IC50) CDK2:3500 nM (IC50) GSK3α:1260 nM (IC50) |
In Vitro | GSK269962A has an IC50 of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases[1]. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM[1]. |
In Vivo | GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial[1]. Animal Model: Male Sprague-Dawley rats (350-400g)[1] Dosage: 0.3, 1, and 3 mg/kg Administration: Oral gavage; 12 hours Result: Induced a dose-dependent reduction in blood pressure. |
References |
Molecular Formula | C29H31ClN8O5 |
---|---|
Molecular Weight | 607.06 |